Literature DB >> 3488199

Inhibition of the beta-lactamases of Branhamella catarrhalis by clavulanic acid and other inhibitors.

T Farmer, C Reading.   

Abstract

The beta-lactamases of Branhamella catarrhalis Ravasio and strain 1908 were readily inhibited by low concentrations of sulbactam, beta-halopenicillanic acids, MM 13902 and clavulanic acid. More detailed studies on the interaction of the Ravasio beta-lactamase with clavulanic acid demonstrated that the enzyme had high affinity for the inhibitor (Ki = 0.07 mumol/L) and was rapidly inhibited (t1/2 = 21 sec, kinhib. = 0.033/sec). Two types of enzyme-inhibitor complex were formed, a transiently stable species (t1/2 = 5.3 minutes at pH 7.3 and 37 degrees C) and a more stable species (t1/2 approximately equal to 2 hours at pH 7.3 and 37 degrees C). Irreversible inactivation of the enzyme was not achieved. Permeability studies on whole cells showed that beta-lactam antibiotics and beta-lactamase inhibitors readily penetrated the outer membrane of B. catarrhalis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3488199     DOI: 10.2165/00003495-198600313-00015

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  14 in total

1.  Clavulanic acid: a beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus.

Authors:  C Reading; M Cole
Journal:  Antimicrob Agents Chemother       Date:  1977-05       Impact factor: 5.191

2.  Novel beta-lactamase from Branhamella catarrhalis.

Authors:  A B Hoi-Dang; C Brive-Le Bouguenec; M Barthelemy; R Labia
Journal:  Ann Microbiol (Paris)       Date:  1978-10

3.  beta-Lactamases of Branhamella catarrhalis and their inhibition by clavulanic acid.

Authors:  T Farmer; C Reading
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

4.  Pathogenicity of and beta-lactamase production by Branhamella (Neisseria) catarrhalis.

Authors:  A Percival; J E Corkill; J Rowlands; R B Sykes
Journal:  Lancet       Date:  1977-12-03       Impact factor: 79.321

5.  Bronchopulmonary infection due to beta-lactamase-producing Branhamella catarrhalis treated with amoxycillin/clavulanic-acid.

Authors:  G Ninane; J Joly; M Kraytman; P Piot
Journal:  Lancet       Date:  1978-07-29       Impact factor: 79.321

6.  Kinetic studies on the inactivation of Escherichia coli RTEM beta-lactamase by clavulanic acid.

Authors:  J Fisher; R L Charnas; J R Knowles
Journal:  Biochemistry       Date:  1978-05-30       Impact factor: 3.162

7.  Porin channels in Escherichia coli: studies with beta-lactams in intact cells.

Authors:  H Nikaido; E Y Rosenberg; J Foulds
Journal:  J Bacteriol       Date:  1983-01       Impact factor: 3.490

8.  Branhamella catarrhalis: antibiotic sensitivities and beta-lactamases.

Authors:  E E Stobberingh; B I Davies; C P van Boven
Journal:  J Antimicrob Chemother       Date:  1984-01       Impact factor: 5.790

9.  Function of the outer membrane of Escherichia coli as a permeability barrier to beta-lactam antibiotics.

Authors:  W Zimmermann; A Rosselet
Journal:  Antimicrob Agents Chemother       Date:  1977-09       Impact factor: 5.191

10.  Olivanic acids, a family of beta-lactam antibiotics with beta-lactamase inhibitory properties produced by Streptomyces species. II. Isolation and characterisation of the olivanic acids MM 4550, MM 13902 and MM 17880 from Streptomyces olivaceus.

Authors:  J D Hood; S J Box; M S Verrall
Journal:  J Antibiot (Tokyo)       Date:  1979-04       Impact factor: 2.649

View more
  6 in total

Review 1.  Antimicrobial susceptibility testing of Haemophilus influenzae, Branhamella catarrhalis, and Neisseria gonorrhoeae.

Authors:  G V Doern; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

2.  In vitro activities of 39 antimicrobial agents for Branhamella catarrhalis and comparison of results with different quantitative susceptibility test methods.

Authors:  G V Doern; T A Tubert
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

Review 3.  Branhamella catarrhalis: an organism gaining respect as a pathogen.

Authors:  B W Catlin
Journal:  Clin Microbiol Rev       Date:  1990-10       Impact factor: 26.132

Review 4.  Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.

Authors:  K McGregor; B J Chang; B J Mee; T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

5.  Characterization of cell-bound papain-soluble beta-lactamases in BRO-1 and BRO-2 producing strains of Moraxella (Branhamella) catarrhalis and Moraxella nonliquefaciens.

Authors:  I Eliasson; C Kamme; M Vang; S G Waley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-04       Impact factor: 3.267

6.  Detection of beta-lactamase activity among clinical isolates of Branhamella catarrhalis with six different beta-lactamase assays.

Authors:  G V Doern; T A Tubert
Journal:  J Clin Microbiol       Date:  1987-08       Impact factor: 5.948

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.